MicroRNA 95 (miR-95)

MicroRNA 95 (miR-95) is a short (20–24 nucleotide) non-coding RNA molecule encoded by the MIR95 gene in humans. It functions as a post-transcriptional regulator of gene expression by binding to mRNAs and either inhibiting their translation or leading to their degradation through incorporation into the RNA-induced silencing complex (RISC)[1][7]. miR-95 has been shown to promote cell proliferation and inhibit apoptosis in various cancer cell types, and is upregulated in certain tumors and muscle differentiation models[2][3]. It also regulates skeletal muscle development by targeting genes such as AIMP2, affecting myogenic differentiation[3]. In osteosarcoma, high serum levels of miR-95-3p are associated with disease presence and progression, making it a potential biomarker and therapeutic target[2]. miR-95 also controls lysosomal function and autophagy by targeting genes such as SUMF1, thereby impacting metabolic pathways and protein catabolism, which has implications for metabolic diseases such as multiple sulfatase deficiency[5]. Because miRNAs target many genes, therapeutic modulation of miR-95 could carry significant risks of unintended biological effects[5].

Other names

MIR95hsa-mir-95MIRN95miR-95

Not classically drug-targeted; exogenous modulation (e.g., miRNA mimics/inhibitors) either blocks or enhances its function, affecting downstream gene expression, mRNA translation inhibition, mRNA destabilization